About Us
- Christchurch Clinical Studies Trust Limited (CCST) provides world class research facilities and the expertise to perform first in human, early Phase I and II studies pharmacokinetic and pharmacodynamics studies in healthy volunteer and patient populations.
- We have a 20 year history of success as a centre of excellence conducting over 250 complex early phase clinical trials in healthy subject and patient populations.
- Our success is due to our people. Our team has a wealth of clinical trial experience and are fully committed to CCST and the research we produce.
- CCST is approved and certified as a clinical research site by Medsafe under New Zealand legislation (Section 30 of the Medicines Act 1981). An FDA inspection in 2017 had no findings.
Why use CCST for your next clinical study?
- State of the art 30 bed medical research facility.
- 20 years of experience with over 250 clinical trials in healthy subject and patient populations completed.
- Database of over 15,000 volunteers and the ability to source patient populations as required.
- 100% of studies fully recruited since 2015 with very high study completion rate and very low rate of missed visits – recently only 0.2% of visits were missed in a large biosimilar study conducted at CCST.
- Centralised Ethics committees and short approval times.
- Strong collaborator networks – two sites working with complimentary standard operating procedures to complete clinical trials in NZ.
- The CCST team has many years of clinical trial experience and are all committed to being your partner in quality early stage clinical research.
- Our quality management is in alignment with all recognised international standards.
- FDA inspection in 2017 with no findings.
About CCST
- CCST is a research facility established by Professor Richard Robson in Consultant Nephrologist and Pharmacologist in 1999. Dr Chris Wynne, Consultant Radiation Oncologist and Principal Investigator joined CCST as Medical Director in 2004.
- In October 2018, CCST moved to a purpose built state of the art research facility with a fully equipped processing laboratory, temperature controlled pharmacy, on site CRA monitoring, medical and quality assurance facilities.
- We are located in Te Papa Hauora. This newly developed health precinct includes our strategic partners, Christchurch Hospital and Canterbury Health Laboratories. CCST has strong alliances with the Christchurch Hospital and School of Medicine. We collaborate with local world class researchers who are keen to participate in joint ventures and recruit patients for Phase II studies.
- CCST benefits from New Zealand’s centralised Ethics committees, short Ethics approval times (Time from final protocol to EC approval is 4-6 weeks.) and efficient application processes. Our Medical Director, Professor Robson chairs the SCOTT Committee which undertakes scientific assessment of applications to conduct trials in New Zealand. Dr Chris Wynne is a SCOTT committee member. Our Ethics consultant is Dr Devonie Waaka. These consultants are well respected and published in the field of clinical research.
- We are a preferred Iqvia partner with a Global Certificate of Excellence awarded in 2107 for quality of work in clinical trials. We were FDA inspected in 2017 with no findings. We are a Strategic Alliance Partner of Genentech.
- CCST values its dedication to quality, as seen in the introduction of a fully electronic quality management system (Q-Pulse).
Recent clinical study highlights
- Together with our sister site, Auckland Clinical Studies, we recently entered 696 subjects into the largest biosimilar study ever undertaken. A key result was that only 0.2% of visits were not carried out.
- CCST also recently recruited 142 study participants in a six week period for another key study.
- Recent study recruited, vaccinated and dosed 114 subjects which included additional numbers as a rescue site.
Our Experience
CCST is known as a centre of excellence for Phase 1 and 2 healthy subject and patient studies. We add to our expertise by utilising consultant specialists from multiple fields when required. Our healthy volunteer studies have ranged from entry in human single ascending dose trials to bioequivalence / food effect studies. Many of these studies have been critical path for sponsors. RACE Study results.
CCST has been able to meet all requirements and timelines.
CCST conducts the following types of studies:
- Entry – in – human
- Small and Large Molecule
- Umbrella Protocols (SAD/ MAD/FE/ Patient)
- Proof of Concept
- Renal Impairment
- Hepatitis
- Oncology
- Paediatric Phase 3
- Device
- Smoking / Vapping
- Drug interaction
- Bioavailability / Food Effect Studies
We help facilitate investigator led studies and have infectious disease experience.
CCST enjoys a strong partnership with our sponsors.
Our previous collaborators:
AbbVie Abxis, Achillion, AFT, Akesobio, Alder Biopharmaceuticals Inc, Alios Biopharma, Alvotech, Amgen, Antipodean, Antisoma, Apellis, Arena Pharmaceuticals, Arrow Astellas, Aurobindo, AzurRx, Betta, BHT, Biogen, Biothera, Boehringer Ingelheim, Breathe Easy Ltd, BristolMyersSquibb, Cawthron Institute, ChemCentryx Inc, Chimerix Inc, CIPLA BioTec, Corcept, Dexcom, Dr Reddy’s Lab, Eli Lilley, FSANZ, Genentech, Gilead, GSK, Health NZ, Idenix, ImmusanT, Ionis ISU, Juul, MedImmune Ltd, Medtronic, Merck Sharpe and Dohme, Mycenax Biotech, NGM, Nova Nordisk, Novartis, Pax Pharmaceutical Research Institute, Pharmacia + UpJohn, Philip Morris Products, SA Ploom, Prestige Biopharma, QUE Oncology, Regeneron Pharmaceuticals, Resverlogix, Roche, Santaris, Semnur, Servier, Symvivo, The Medicines Company, CuraSen, Vaxart Inc, Vertex, Xenetic Biosciences, Otago University, Christchurch Hospital.
